{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:01:45Z","timestamp":1786989705974,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":201,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007162","name":"University of Nevada Las Vegas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007162","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.gastha.2025.100752","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T15:15:24Z","timestamp":1753370124000},"page":"100752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Liver Enzymes Among Patients With Cystic Fibrosis: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9328-0522","authenticated-orcid":false,"given":"Tahne","family":"Vongsavath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyaw Min","family":"Tun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwaipayan","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Han","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Twohig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sammy","family":"Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignan","family":"Manne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastha.2025.100752_bib1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3390\/jcm11020318","article-title":"Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review","volume":"11","author":"Dagenais","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.gastha.2025.100752_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00018-016-2391-y","article-title":"Role of CFTR in epithelial physiology","volume":"74","author":"Saint-Criq","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.gastha.2025.100752_bib3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fphar.2019.00121","article-title":"Emerging therapeutic approaches for cystic fibrosis. From gene editing to personalized medicine","volume":"10","author":"Pranke","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.gastha.2025.100752_bib4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.gastha.2025.100752_bib5","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/MCP.0000000000000824","article-title":"Emerging clinical perspectives in cystic fibrosis liver disease","volume":"27","author":"Athwal","year":"2021","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.gastha.2025.100752_bib6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jcf.2019.09.016","article-title":"Occurrence, outcomes and predictors of portal hypertension in cystic fibrosis: a longitudinal prospective birth cohort study","volume":"19","author":"Cipolli","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.gastha.2025.100752_bib7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrgastro.2015.226","article-title":"Cystic fibrosis from the gastroenterologist's perspective","volume":"13","author":"Ooi","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2025.100752_bib8","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.4254\/wjh.v13.i11.1727","article-title":"Cystic fibrosis associated liver disease in children","volume":"13","author":"Valamparampil","year":"2021","journal-title":"World J Hepatol"},{"key":"10.1016\/j.gastha.2025.100752_bib9","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/lt.20571","article-title":"The role of liver transplantation in cystic fibrosis re-examined","volume":"11","author":"Jonas","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastha.2025.100752_bib10","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastha.2025.100752_bib11","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/MCP.0000000000000423","article-title":"Effects of new and emerging therapies on gastrointestinal outcomes in cystic fibrosis","volume":"23","author":"Houwen","year":"2017","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.gastha.2025.100752_bib12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/biomedicines10010083","article-title":"Intestinal barrier and permeability in health, obesity and NAFLD","volume":"10","author":"Portincasa","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.gastha.2025.100752_bib13","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.gastha.2025.100752_bib14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2147\/CLEP.S66677","article-title":"Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank","volume":"6","author":"Margulis","year":"2014","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.gastha.2025.100752_bib15","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/liv.15544","article-title":"Increase of liver stiffness and altered bile acid metabolism after triple CFTR modulator initiation in children and young adults with cystic fibrosis","volume":"43","author":"Schnell","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.gastha.2025.100752_bib16","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000010","article-title":"Effects of CFTR modulators on serum biomarkers of liver fibrosis in children with cystic fibrosis","volume":"7","author":"Levitte","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.gastha.2025.100752_bib17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jcf.2021.07.018","article-title":"Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR","volume":"21","author":"Drummond","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.gastha.2025.100752_bib18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4254\/wjh.v14.i2.411","article-title":"Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis","volume":"14","author":"Ramsey","year":"2022","journal-title":"World J Hepatol"},{"key":"10.1016\/j.gastha.2025.100752_bib19","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jcf.2020.06.015","article-title":"Lumacaftor\/ivacaftor improves liver cholesterol metabolism but does not influence hypocholesterolemia in patients with cystic fibrosis","volume":"20","author":"Gelzo","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.gastha.2025.100752_bib20","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijpam.2021.10.003","article-title":"Ivacaftor in Omani children with cystic fibrosis caused by p.Ser549Arg CFTR mutation","volume":"9","author":"Al Oraimi","year":"2022","journal-title":"Int J Pediatr Adolesc Med"},{"key":"10.1016\/j.gastha.2025.100752_bib21","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1177\/21925682221110527","article-title":"Fixed-effect vs random-effects models for meta-analysis: 3 points to consider","volume":"12","author":"Dettori","year":"2022","journal-title":"Glob Spine J"},{"key":"10.1016\/j.gastha.2025.100752_bib22","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jrsm.1348","article-title":"Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions","volume":"10","author":"Schwarzer","year":"2019","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.gastha.2025.100752_bib23","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/hep.28817","article-title":"The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity","volume":"64","author":"Fiorotto","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2025.100752_bib24","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.cytogfr.2014.06.002","article-title":"Tyrosine phosphorylation in Toll-like receptor signaling","volume":"25","author":"Chattopadhyay","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.gastha.2025.100752_bib25","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/clpt.2012.108","article-title":"Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, present, and future","volume":"92","author":"Senior","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.gastha.2025.100752_bib26","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/hep.23358","article-title":"Alanine aminotransferase: is it healthy to be \"normal\"?","volume":"50","author":"Dufour","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2025.100752_bib27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clinbiochem.2020.02.006","article-title":"Defining appropriate utilization of AST testing","volume":"79","author":"Mohammed-Ali","year":"2020","journal-title":"Clin Biochem"},{"key":"10.1016\/j.gastha.2025.100752_bib28","article-title":"Impact of CFTR modulator therapies on liver function in cystic fibrosis patients: a systematic review of hepatic biomarkers","author":"Moiceanu","year":"2024","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.gastha.2025.100752_bib29","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastha.2025.100752_bib30","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2213-2600(18)30460-0","article-title":"Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study","volume":"7","author":"McNamara","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.gastha.2025.100752_bib31","first-page":"32","article-title":"Can the histologic changes of cystic fibrosis-associated hepatobiliary disease be predicted by clinical criteria?","volume":"25","author":"Potter","year":"1997","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastha.2025.100752_bib32","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.gastha.2025.100752_bib33","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1080\/14740338.2017.1372419","article-title":"The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis","volume":"16","author":"Talamo Guevara","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.gastha.2025.100752_bib34","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fphar.2016.00275","article-title":"CFTR modulators: shedding light on precision medicine for cystic fibrosis","volume":"7","author":"Lopes-Pacheco","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.gastha.2025.100752_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113195","article-title":"Modulators of CFTR. Updates on clinical development and future directions","volume":"213","author":"Bardin","year":"2021","journal-title":"Eur J Med Chem"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572325001396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572325001396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T07:04:41Z","timestamp":1761375881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572325001396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"alternative-id":["S2772572325001396"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2025.100752","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Liver Enzymes Among Patients With Cystic Fibrosis: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2025.100752","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}],"article-number":"100752"}}